Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
2 hedge funds and large institutions have $628 invested in Reviva Pharmaceuticals Warrants in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0.19% less ownership
Funds ownership: 0.2% → 0.01% (-0.19%)
33% less funds holding
Funds holding: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
92% less capital invested
Capital invested by funds: $8.12K → $628 (-$7.49K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$518 |
| 2 |
CS
Clear Street
New York
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$4.55K |
| 2 |
Walleye Trading
New York
|
-$3.47K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $612 | +$518 | +3,068 | +461% |
|
|
CS
2
Clear Street
New York
| $16 | +$17 | +100 | New |
|
|
3
Walleye Capital
New York
| – | -$4.55K | -33,718 | Closed |
|
|
4
Walleye Trading
New York
| – | -$3.47K | -25,727 | Closed |
|
RVPHW Hedge Fund Activity: Q4 2024 in Review
2 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q4 2024, worth a combined $628 — down 92% from $8.12K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of RVPHW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $518. The largest seller was Walleye Capital, exiting entirely with an estimated $4.55K sold.
- 2 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q4 2024, down from 3 in Q3 2024.
- Funds reported $628 of Reviva Pharmaceuticals Warrants stock for Q4 2024, down 92% quarter-over-quarter.
- 1 fund opened new Reviva Pharmaceuticals Warrants positions in Q4 2024 and 2 closed out, a net change of -1 holder.
- The largest Reviva Pharmaceuticals Warrants buyer in Q4 2024 was UBS Group, an estimated $518 added.
- The largest Reviva Pharmaceuticals Warrants seller in Q4 2024 was Walleye Capital, an estimated $4.55K sold.
Based on aggregated 13F filings for Q4 2024.